被忽視的熱帶病治療的全球市場2022-2029
市場調查報告書
商品編碼
1153807

被忽視的熱帶病治療的全球市場2022-2029

Global Neglected Tropical Disease Treatment Market - 2022-2029

出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

在預測期內(2022-2029 年),被忽視熱帶病治療的全球市場規模預計將以 5.55% 的複合年增長率增長。

被忽視的熱帶病 (NTD) 是 20 種主要在熱帶地區發現的疾病,對窮人、婦女和兒童的影響尤為嚴重。這些疾病對人們的健康、社會和經濟造成破壞性影響。許多被忽視的熱帶病 (NTD) 可以用現有藥物治療。有些治療很容易應用,不需要專家的幫助。同時,藥物治療可用於某些被忽視的熱帶病,但並不總能到達最需要的人手中。

市場動態

被忽視的熱帶病治療市場的增長背後有幾個因素,包括全球組織的努力、發達國家移民人口的增加以及發展中國家缺乏足夠的衛生設施和意識。

針對被忽視的熱帶病的藥物發現不斷增加的資金預計將推動市場增長。

最近為平衡對被忽視的熱帶病和其他疾病的投資所做的國際努力開始改變這一局面。例如,根據第一份年度報告,估計每年的資金缺口為 3 億美元。根據第三次進展報告,製藥公司已承諾到2020年為10種疾病提供價值178億美元的藥物。此外,世衛組織最近歡迎設立一個 1 億美元的基金,以幫助消除兩種毀滅性的傳染性 NTD:盤尾絲蟲病(河盲症)和淋巴絲蟲病(像皮病)。阿布扎比王儲和比爾及梅琳達蓋茨基金會各捐助 2000 萬美元,其餘 6000 萬美元來自與其他捐助者和基金會的合作。由於這些原因,預計市場將成為預測期內的推動力。

約束

由於對被忽視的熱帶病的治療認識不足,銷售額正在下降。被忽視的熱帶病無法獲□□得尖端藥物,醫療保健系統也不完善。因此,預計上述因素將在預測期內成為障礙。

行業分析

被忽視的熱帶病治療市場根據波特五力、供應鏈、定價分析和監管批准等各種行業因素對市場進行了深入分析。

內容

第一章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第四章市場動態

  • 市場影響因素
    • 司機
      • 由於針對被忽視的熱帶病的藥物發現資金增加,預計市場會增長。
    • 約束因素
      • 認知度低預計會阻礙預測期內的市場增長。
    • 市場機會
    • 影響分析

第五章行業分析

  • 搬運工的五種力量
  • 未滿足的需求
  • 供應鏈
  • 定價分析
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按疾病類型分類

  • 布魯裡潰瘍
  • 南美錐蟲病
  • 登革熱/基孔肯雅熱
  • 德古拉病
  • 包蟲病
  • 食物中毒吸蟲
  • 非洲人類錐蟲病
  • 利甚曼病
  • 麻風病
  • 淋巴絲蟲病
  • 菌絲體、黑色素瘤芽生菌病
  • 盤尾絲蟲病
  • 狂犬病
  • 疥瘡
  • 血吸蟲病
  • 土傳蠕蟲病
  • 蛇咬傷
  • 絛蟲病/囊尾蚴病
  • 沙眼
  • 溜溜球

第 8 章按治療類型分類

  • 藥物治療
  • 疫苗

第 9 章(按銷售渠道)

  • 醫院藥房
  • 零售藥房
  • 在線藥店

第10章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第11章競爭格局

  • 競爭場景
  • 市場情況/份額分析
  • 併購分析

第12章公司簡介

  • Bayer AG
    • 公司概況
    • 產品組合和說明
    • 主要亮點
    • 財務摘要
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Novartis AG
  • Pfizer Inc.
  • Cipla Limited
  • AbbVie Inc.
  • Takeda Pharmaceuticals
  • Serum Institute of India
  • Visterra Inc.

第13章 被忽視的熱帶病治療的全球市場-DataM

簡介目錄
Product Code: DMPH1231

Market Overview

The global neglected tropical disease treatment market size was valued US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 5.55% during the forecast period (2022-2029).

Neglected tropical diseases (NTDs) are a series of 20 diseases mostly found in tropical areas, disproportionately impacting poor people, women and children. People suffer from terrible health, societal, and economic effects due to these disorders. Many neglected tropical diseases (NTDs) are curable with existing medications. Certain therapies are simple to apply and do not necessitate the use of medical specialists. In contrast, while medication therapies are available for several NTDs, they do not always reach the people who need them the most.

Market Dynamics

The neglected tropical disease treatment market growth is driven by several factors, such as initiatives taken by several organizations globally, increase in migrant population in developed nations, and a lack of proper sanitation and awareness in developing countries.

Increasing funding for drug discovery for the neglected tropical disease is expected to drive market growth.

Recent international efforts to balance the investment between neglected and other diseases have begun reshaping the landscape. For instance, according to the first annual report, the estimated financing gap is $300 million per year. According to the third progress report, pharmaceutical companies have pledged medications worth $17.8 billion for the ten diseases until 2020. Moreover, WHO recently welcomed the establishment of a $100 million fund to aid in eradicating two devastating infectious NTDs: onchocerciasis (river blindness) and lymphatic filariasis (elephantiasis). The Crown Prince of Abu Dhabi and the Bill and Melinda Gates Foundation have each pledged US$20 million, with the remaining US$60 million generated through collaboration with other donors and foundations. Thus, from the above statements, the market is expected to drive in the forecast period.

Restraint

Lack of awareness cause sales of neglected tropical disease treatment options to fall. These nations lack access to cutting-edge drugs and an inadequate healthcare system. Thus, the abovementioned factors are expected to get hampered in the forecast period.

Industry Analysis

The neglected tropical disease treatment market provides in-depth analysis of the market based on various industry factors such as porter five forces, supply chain, pricing analysis, regulatory approvals etc.

Segment Analysis

Medication segment is expected to hold the largest market share in neglected tropical disease treatment market.

The medication segment accounted for the largest market share in 2021. The segment is further sub-segmented into antibiotic, antiparasitic, anti-inflammatory, anti-microbial, and anti-fungal. Among medications, antiparasitic drugs are most commonly used for treating neglected tropical diseases, as many of them are caused by parasitic transmission. The high prevalence of parasite-infected diseases in remote and rural areas and urban slums due to poor sanitation practices have increased the demand for antiparasitic drugs. Several FDA-approved antiparasitic drugs are on the market to treat neglected tropical diseases, and many major players are developing new and advanced medicines for faster treatment. For instance, on November 8, 2021, Orlando, Fla-based Profounda announced the Food and Drug Administration (FDA) approved an Orphan Drug Designation for the use of the company's therapy, miltefosine (Impavido), to treat invasive candidiasis. Miltefosine is an oral, FDA-approved treatment for visceral, mucosal, and cutaneous leishmaniasis in individuals aged 12 and up. Thus, from the above statements, the markert segment accounted for the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global neglected tropical disease treatment market

North America accounted for the largest market share in 2021. Owing to the highly aware population, advanced healthcare infrastructure, favorable government initiatives, increase in migrant population over the region and presence of major companies. North America has the requisite insect vectors, the climate, and the ecology to support the presence of these diseases and, of course, a susceptible human population to become infected. North America has the requisite insect vectors, the climate, and the ecology to support the presence of these diseases and, of course, a susceptible human population to become infected. According to the Centers for Disease Control and Prevention (CDC), Chagas disease is the new HIV in the U.S., with around 300,000 people suffering from it and about 315 babies born with it yearly. Moreover, in March 2019, Novartis joined the Global Chagas Disease Coalition and announced the first multinational, prospective, randomized study in people with chronic Chagas cardiomyopathy. Thus, from the above statements, the North American region accounted for the largest market share in the forecast period.

Competitive Landscape

Major key players in the neglected tropical disease treatment market are: Bayer AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Novartis AG, Pfizer Inc., Cipla Limited, AbbVie Inc., Takeda Pharmaceuticals, Serum Institute of India and, Visterra Inc.

Bayer AG:

Overview:

Bayer is a Life Science company with a more than 150-year history and core health care and agriculture competencies. The Bayer Group is managed as a life science company with three divisions Pharmaceuticals, Consumer Health and Crop Science, which are also our reporting segments. The Enabling Functions support the operational business. In 2019, the Bayer Group comprised 392 consolidated companies in 87 countries. The Pharmaceuticals division focuses on prescription products, especially cardiology and women's healthcare, and specialty therapeutics in oncology, hematology and ophthalmology. The Consumer Health division markets mainly nonprescription (OTC) products in the dermatology, nutritional supplement, analgesic, digestive health, cold, allergy, sinus and flu categories.

Product Portfolio:

Praziquantel (Biltricide): This medication is used to treat infections of certain parasites (such as Schistosoma and liver flukes). Curing parasitic infections helps to improve your health and quality of life. Praziquantel belongs to a class of drugs known as anthelmintics. It works by killing the parasites.

The global neglected tropical disease treatment market report would provide an access to an approx. 45+ market data table, 40+ figures and 180 pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing funding for drug discovery for the neglected tropical disease is expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. Lack of awareness are expected to get hampered in the forecast period.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces
  • 5.2. Unmet Needs
  • 5.3. Supply Chain
  • 5.4. Pricing Analysis
  • 5.5. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Disease Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 7.1.2. Market Attractiveness Index, By Disease Type Segment
  • 7.2. Buruli Ulcer*
      • 7.2.1.1. Introduction
      • 7.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Chagas Disease
  • 7.4. Dengue and Chikungunya
  • 7.5. Dracunculiasis
  • 7.6. Echinococcosis
  • 7.7. Foodborne Trematodiases
  • 7.8. Human African Trypanosomiasis
  • 7.9. Leishmaniasis
  • 7.10. Leprosy
  • 7.11. Lymphatic Filariasis
  • 7.12. Mycetoma, Chromoblastomycosis
  • 7.13. Onchocerciasis
  • 7.14. Rabies
  • 7.15. Scabies
  • 7.16. Schistosomiasis
  • 7.17. Soil-transmitted Helminthiases
  • 7.18. Snakebite Envenoming
  • 7.19. Taeniasis/Cysticercosis
  • 7.20. Trachoma
  • 7.21. Yaws

8. By Treatment Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.1.2. Market Attractiveness Index, By Treatment Type Segment
  • 8.2. Medication*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Vaccines

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel Segment
  • 9.2. Hospital pharmacies*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Retail pharmacies
  • 9.4. Online pharmacies

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Bayer AG*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. F. Hoffmann-La Roche Ltd.
  • 12.3. GlaxoSmithKline Plc
  • 12.4. Novartis AG
  • 12.5. Pfizer Inc.
  • 12.6. Cipla Limited
  • 12.7. AbbVie Inc.
  • 12.8. Takeda Pharmaceuticals
  • 12.9. Serum Institute of India
  • 12.10. Visterra Inc.

LIST NOT EXHAUSTIVE

13. Global Neglected Tropical Disease Treatment Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Applications
  • 13.3. Contact Us